Anti-inflammatory actions of St. John's Wort: Inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1α (STAT-1α) activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 1, 2003, Pages 254-261

  Tedeschi, Elisa ^a   Menegazzi, Marta ^a   Margotto, Daniela ^a   Suzuki, Hisanori ^a   Förstermann, Ulrich ^b   Kleinert, Hartmut ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERICUM PERFORATUM EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; JANUS KINASE; JANUS KINASE 2; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; STAT1 PROTEIN; STAT1ALPHA PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; COLON MUCOSA; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; DNA BINDING; DOWN REGULATION; DRUG INHIBITION; ENZYME ACTIVITY; EPITHELIUM CELL; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INDUCIBLE NITRIC OXIDE SYNTHASE GENE; INFLAMMATORY DISEASE; INTERLEUKIN 6 GENE; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; TRANSCRIPTION REGULATION;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DNA; DOWN-REGULATION; GENE EXPRESSION; HUMANS; HYPERICUM; INTERFERON-STIMULATED GENE FACTOR 3; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PLANT EXTRACTS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0141742433     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.054460     Document Type: Article

References (40)

1. Adcock IM (1997) Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 52:178-186.
2. Agostinis P, Donella-Deana A, Cuveele J, Vandenbogaerde A, Sarno S, Merlevede W, and de Witte P (1996) A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives. Biochem Biophys Res Commun 220:613-617.
3. Alderton WK, Cooper CE, and Knowles RG (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357:593-615.
4. Barnes J, Anderson LA, and Phillipson JD (2001) St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 53:583-600.
5. Bork PM, Bacher S, Schmitz ML, Kaspers U, and Heinrich M (1999) Hypericin as a non-antioxidant inhibitor of NF-kappa B. Planta Med 65:297-300.
6. Briscoe J, Rogers NC, Witthuhn BA, Watling D, Harpur AG, Wilks AF, Stark GR, Ihle JN, and Kerr IM (1996) Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO (Eur Mol Biol Organ) J 15:799-809.
7. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Ciliberto G, Parisi A, De Sarro G, and Caputi AP (2001) Interleukin-6 involvement in antidepressant action of Hypericum perforatum. Pharmacopsychiatry 34 (Suppl 1):S8-S10.
8. Darnell JE Jr, Kerr IM, and Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Wash DC) 264:1415-1421.
9. Dell'Albani P, Santangelo R, Torrisi L, Nicoletti VG, de Vellis J, and Giuffrida Stella AM (2001) JAK/STAT signaling pathway mediates cytokine-induced iNOS expression in primary astroglial cell cultures. J Neurosci Res 65:417-424.
10. Fiebich BL, Hollig A, and Lieb K (2001) Inhibition of substance P-induced cytokine synthesis by St. John's wort extracts. Pharmacopsychiatry 34 (Suppl 1):S26-S28.
11. Ganster RW, Taylor BS, Shao L, and Geller DA (2001) Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc Natl Acad Sci USA 98:8638-8643.
12. Geller DA and Billiar TR (1998) Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 17:7-23.
13. Guslandi M (1998) Nitric oxide and inflammatory bowel diseases. Eur J Clin Investig 28:904-907.
14. Hausding M, Witteck A, Rodriguez-Pascual F, von Eichel-Streiber M, Förstermann U, and Kleinert H (2000) Inhibition of small G proteins of the Rho family enhances cytokine-mediated induction of NO synthase II. Br J Pharmacol 131:553-561.
15. Husain K (2002) Exercise conditioning attenuates the hypertensive effects of nitric oxide synthase inhibitor in rat. Mol Cell Biochem 231:129-137.
16. Ihle JN (1995) Cytokine receptor signalling. Nature (Lond) 377:591-594.
17. Jaiswal M, LaRusso NF, and Gores GJ (2001) Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 281:G626-G634.
18. Kim YM, deVera ME, Watkins SC, and Billiar TR (1997) Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha induced apoptosis by inducing heat shock protein 70 expression. J Biol Chem 272:1402-1411.
19. Kleinert H, Boissel JP, Schwarz PM, and Förstermann U (2000) Regulation of the expression of nitric oxide synthase isoforms, in Nitric Oxide: Biology and Pathobiology (Ignarro LJ ed) pp 105-128, Academic Press, New York.
20. Kleinert H, Euchenhofer C, Ihrig-Biedert I, and Förstermann U (1996) Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B. Mol Pharmacol 49:15-21.
21. Kleinert H, Wallerath T, Fritz G, Ihrig-Biedert I, Rodriguez-Pascual F, Geller DA, and Förstermann U (1998) Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-κB-signaling pathways. Br J Pharmacol 125:193-201.
22. Kröncke KD, Fehsel K, and Kolb-Bachofen V (1998) Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 113:147-156.
23. Leonard N, Bishop AE, Polak JM, and Talbot IC (1998) Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment. J Clin Pathol (Lond) 51:750-753.
24. MacMicking J, Xie QW, and Nathan C (1997) Nitric oxide and macrophage function. Annu Rev Immunol 15:323-350.
25. Makarov SS (2000) NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 6:441-448.
26. Menegazzi M, Tedeschi E, Dussin D, De Prati AC, Cavalieri E, Mariotto S, and Suzuki H (2001) Anti-interferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation. FASEB J 15:1309-1311.
27. Ohmori Y and Hamilton TA (2001) Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol 69:598-604.
28. Osborne KA, Robichon A, Burgess E, Butland S, Shaw RA, Coulthard A, Pereira HS, Greenspan RJ, and Sokolowski MB (1997) Natural behavior polymorphism due to a cGMP-dependent protein kinase of Drosophila. Science (Wash DC) 277:834-836.
29. Payne CM, Bernstein C, Bernstein H, Gerner EW, and Garewal H (1999) Reactive nitrogen species in colon carcinogenesis. Antioxid Redox Signal 1:449-467.
30. Raso GM, Meli R, Di Carlo G, Pacilio M, and Di Carlo R (2001) Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A. 1. Life Sci 68:921-931.
31. Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, and Meli R (2002) In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum. J Pharm Pharmacol 54:1379-1383.
32. Sadeghi MM, Tiglio A, Sadigh K, O'Donnell L, Collinge M, Pardi R, and Bender JR (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation (Baltimore) 71:1262-1268.
33. Schacke H, Docke WD, and Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43.
34. Schwarz JT and Cupp MJ (2000) St John's wort, in Toxicology and Clinical Pharmacology of Herbal Products (Cupp MJ ed) pp 67-78, Humana Press, Inc., Totowa, NJ.
35. Shanley TP, Zhao B, Macariola DR, Denenberg A, Salzman AL, and Ward PA (2002) Role of nitric oxide in acute lung inflammation: lessons learned from the inducible nitric oxide synthase knockout mouse. Crit Care Med 30:1960-1968.
36. Stallmeyer B, Kampfer H, Kolb N, Pfeilschifter J, and Frank S (1999) The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound reepithelialization. J Investig Dermatol 113:1090-1098.
37. Umansky V and Schirrmacher V (2001) Nitric oxide-induced apoptosis in tumor cells. Adv Cancer Res 82:107-131.
38. Wang J and Mazza G (2002) Inhibitory effects of anthocyanins and other phenolic compounds on nitric oxide production in LPS/IFN-gamma-activated RAW 264.7 macrophages. J Agric Food Chem 50:850-857.
39. Witteck A, Yao Y, Fechir M, Förstermann U, and Kleinert H (2003) Human iNOS gene expression is regulated by Rho protein-mediated changes in the structure of the actin cytoskeleton. Exp Cell Res 287:106-115.
40. Yao Y, Hausding M, Erkel G, Anke T, Forstermann U, and Kleinert H (2003) Sporogen, S14-95 and S-curvularin, three inhibitors of human inducible nitricoxide synthase expression isolated from fungi. Mol Pharmacol 63:383-391.